Our results show that ZEB1 functions as a tumor suppressor in BRAF-mutant CRCs, highlighting the need to assess the mutational background of CRC before using therapies that inhibit the expression and/or function of ZEB1. This evidence concerns the gene ZEB1 and neoplasm.